Research Field

Outcomes of anticancer therapy vary dramatically among patients, and this may be caused by the specific molecular alterations in each patient’s tumor. Precision oncology aims to predict optimal therapies for each tumor based on its particular molecular characteristics. Surrogate systems to characterize and measure patient-specific responses include patient-derived xenografts (PDXs) and tumor-derived cells (PDCs). PDC-and/or patient-deried orgaonid (PDO) based screening systems allow high-throughput generation of reliable drug-response parameters. PDCs provide a rapid and efficient way to probe the unique biology and drug response of individual patients’ tumors. We aim to investigate the clinical relevance of PDCs/PDOs based drug screening and comprehensive analysis with cancer genomic profiles to suggest the best target therapy for an individual cancer patient.

Pure Link

Keyword

Patient-derived Organoid, 3D drug screening, Precision Oncology, Translational Medicine